Results 41 to 50 of about 117,912 (291)

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). [PDF]

, 2018
The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing rapidly due to growing proportion of HPV-related disease and development of new therapeutic agents.
Jung, Kyungsuk, Kang, Hyunseok, Mehra, Ranee   +2 more
core   +2 more sources

Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)

medRxiv, 2021
Introduction: β-thalassemia is caused by autosomal mutations in the β-globin gene, which induce the absence or low-level synthesis of β-globin in erythroid cells.
Cristina Zuccato, L. C. Cosenza, Matteo Zurlo, Jessica Gasparello, C. Papi, Elisabetta D’Aversa, Giulia Breveglieri, I. Lampronti, A. Finotti, M. Borgatti, C. Scapoli, Alice Stievano, M. Fortini, E. Ramazzotti, N. Marchetti, M. Prosdocimi, M. Gamberini, R. Gambari   +17 more
semanticscholar   +1 more source

Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis. [PDF]

PLoS ONE, 2013
We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC).
Izabela A Malinowska, Nancy Lee, Vidhya Kumar, Elizabeth A Thiele, David Neal Franz, Stephen Ashwal, Arthur Sagalowsky, Francis J Dimario, Drew Cutler, Darcy Krueger, Susana Camposano, Jan Paolini, Sandra L Dabora   +12 more
doaj   +1 more source

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. [PDF]

, 2016
PurposeTo determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Materials and methodsPatients who were 1 to 30 years of age
Allen, Shelly, DuBois, Steven G, Gustafson, W Clay, Hollinger, Fabienne, Karski, Erin E, Long-Boyle, Janel R, Matthay, Katherine K, Nasholm, Nicole M, Shiboski, Stephen, Vo, Kieuhoa T   +9 more
core   +1 more source

Sirolimus in the treatment of kaposiform lymphangiomatosis

Orphanet Journal of Rare Diseases, 2021
Background Kaposiform lymphangiomatosis (KLA), which is a new subtype of generalized lymphatic anomaly, is a rare disease with a poor prognosis. Currently, there is no standard treatment due to the poor understanding of KLA.
Jiangyuan Zhou, Kaiying Yang, Siyuan Chen, Yi Ji   +3 more
semanticscholar   +1 more source

Refractory Head and Neck Lymphatic Malformation in Infants Treated With Sirolimus: A Case Series

Frontiers in Oncology, 2021
Background Extensive and complex head and neck lymphatic malformations (LMs) are challenging to manage through traditional therapy. The purpose of this retrospective study was to assess the efficacy and safety of sirolimus in infants with refractory head
Changhua Wu, D. Song, Lei Guo, Liang-liang Wang   +3 more
semanticscholar   +1 more source

Experimental rat models of chronic allograft nephropathy: a review [PDF]

, 2014
Chronic allograft nephropathy (CAN) is the leading cause of late allograft loss after renal transplantation (RT), which continues to remain an unresolved problem. A rat model of CAN was first described in 1969 by White et al. Although the rat model of RT
Haylor, John, Shrestha, Badri
core   +2 more sources

Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies

Pediatrics, 2016
BACKGROUND AND OBJECTIVES: Complicated vascular anomalies have limited therapeutic options and cause significant morbidity and mortality. This Phase II trial enrolled patients with complicated vascular anomalies to determine the efficacy and safety of ...
D. Adams, C. Trenor, A. Hammill, A. Vinks, Manish N. Patel, G. Chaudry, Mary Sue Wentzel, P. Mobberley-Schuman, L. Campbell, C. Brookbank, Anita Gupta, C. Chute, Jennifer Eile, J. McKenna, A. Merrow, Lin Fei, L. Hornung, M. Seid, A. Dasgupta, B. Dickie, R. Elluru, A. Lucky, B. Weiss, R. Azizkhan   +23 more
semanticscholar   +1 more source

Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients

Journal of Lipid Research, 2002
Sirolimus (Rapammune®, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection. Hyperlipidemia is a significant side effect of sirolimus treatment, and frequently leads to cardiovascular disease.
Joel D. Morrisett, Ghada Abdel-Fattah, Ron Hoogeveen, Eddie Mitchell, Christie M. Ballantyne, Henry J. Pownall, Antone R. Opekun, Jonathon S. Jaffe, Suzanne Oppermann, Barry D. Kahan   +9 more
doaj   +1 more source

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

Sarcoma, 2020
Purpose Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas. Combining Hsp90 inhibitors to enhance endoplasmic reticulum stress with mTOR inhibition results in dramatic MPNST shrinkage in a genetically engineered MPNST ...
AeRang Kim, Yao Lu, S. Okuno, D. Reinke, Ophélia Maertens, J. Perentesis, M. Basu, P. Wolters, Thomas De Raedt, S. Chawla, R. Chugh, B. V. Van Tine, Geraldine O'Sullivan, A. Chen, K. Cichowski, B. Widemann   +15 more
semanticscholar   +1 more source